Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Prilocaine

            Therapeutic Area: Psychiatry/Psychology Product Name: Senstend

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 02, 2020


            Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.